Inhibrx cancer drug shows positive mid-stage results
Inhibrx Biosciences announced that its experimental combination cancer drug INBRX-106 successfully shrank tumors in a mid-stage head and neck cancer study. The trial showed significant benefits particularly in patients with HPV-positive disease.
Xurve View
Insights:
Xurve View
INHIBRX BIOSCIENCES INC reported that its experimental combination cancer drug shrank tumors in 48.3% of mid-stage head and neck cancer patients. The trial evaluated INBRX-106 paired with Keytruda against Keytruda alone in 68 patients. The data points toward a competitive profile in a difficult biological target.
